China's Biotech Surge: Regulatory Reform and Market Strategy
China has rapidly surpassed the US in clinical trial volume and novel drug approvals through targeted regulatory reforms. This analysis examines how streamlined ethics approvals, volume-based pricing negotiations, and larger trial enrollments are reshaping global biotech competition. US stakeholders must adapt regulatory frameworks and pricing strategies to maintain innovation leadership.